Research progress on the anti-tumor effects of statins

Abstract

Abstract:

The 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the most prescribed lipid-lowering drugs in clinic on account of their demonstrated safety and efficacy in prevention and treatment of cardiovascular diseases. Beyond their potent inhibition effects in cholesterol biosynthesis, statins appear to have pleiotropic effects in cancer. In the respect of anti-tumor effect, statins could modulate the cell growth, apoptosis, and inflammation, as well as reduce cancer risk and improve survival of patients. There are some scientific controversies in current studies, and more pre-clinical and clinical verification studies are needed. Herein we review the pre-clinical and clinical data relevant to statins and their anti-tumor effects in recent years, and discuss the current status and the potential of statins as chemopreventive drugs in future.

Key words: statins, anti-tumor effect, cell growth, inflammatory response, apoptosis

CLC Number:

R968

DENG Junli, ZHANG Rui, TANG Jie, WANG Guo, ZHU Yuanshan. Research progress on the anti-tumor effects of statins[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 92-99.

References

［1］Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia［J］. N Engl J Med,1988,319(1):24-33.
［2］Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins［J］. Lancet,2005,366(9493):1267-1278.
［3］Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer［J］. Pharmacol Rev,2012,64(1):102-146.
［4］Furuya Y, Sekine Y, Kato H,et al. Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins［J］. Prostate Int, 2016, 4(2):56-60.
［5］Kimbung S, Lettiero B, Feldt M,et al. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer［J］. Oncotarget, 2016 Jul 21.doi: 10.18632/oncotarget.10746. ［Epub ahead of print］
［6］Matusewicz L, Meissner J, Toporkiewicz M, et al.The effect of statins on cancer cells--review［J］. Tumour Biol,2015,36(7):4889-4904.
［7］Stryjkowska-Góra A, Karczmarek-Borowska B, Góra T,et al. Statins and cancers［J］. Contemp Oncol (Pozn), 2015,19(3):167-175.
［8］Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011,47(6):819-830.
［9］Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer［J］. Pharmacol Rev,2012,64(1):102-146.
［10］Duncan RE, El-Sohemy A, Archer MC.Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity［J］. J Biol Chem,2004,279(32):33079-33084.
［11］Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins［J］. Oncogene,2012,31(48):4967-4978.
［12］Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase［J］. Proc Natl Acad Sci USA. 1999,96(14):7797-7802.
［13］Tu YS, Kang XL, Zhou JG, et al. Involvement of Chk1-Cdc25A-cyclin A/CDk2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells［J］. Eur J Pharmacol,2011,670(2/3):356-364.
［14］Spampanato C, De Maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and downregulation of BCL-2 gene expression［J］. Int J Oncol,2012,40(4):935-941.
［15］Herrero-Martin G, Lopez-Rivas A. Statins activate a mitochondriaoperated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins［J］. FEBS Lett,2008,582(17):2589-2594.
［16］Buranrat B, Senggunprai L, Prawan A, et al. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells［J］. Life Sci,2016,153:41-49.
［17］Xie F, Liu J, Li C, et al. Simvastatin blocks TGF-β1-induced epithelial-mesenchymal transition in human prostate cancer cells［J］. Oncol Lett, 2016,11(5):3377-3383.
［18］Wolfe AR, Debeb BG, Lacerda, et al. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a［J］. Breast Cancer Res Treat,2015,154(3):495-508.
［19］Al-Haidari AA, Syk I, Thorlacius H. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation［J］. Biochem Biophys Res Commun,2014,446(1):68-72.
［20］Afshordel S, Kern B, Clasohm J, et al. Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation--impact of Ras-/Rho-prenylation［J］. Pharmacol Res,2015,91:69-77.
［21］Gan J, Li P, Wang Z, et al. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway［J］. Exp Ther Med,2013,6(4):899-903.
［22］Schointuch MN, Gilliam TP, Stine JE, et al. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer［J］. Gynecol Oncol,2014,134(2):346-355.
［23］Stine JE, Guo H, Sheng X, et al. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer［J］. Oncotarget,2016,7(1):946-960.
［24］Fang Z, Tang Y, Fang J,et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway［J］. PLoS One,2013,8(5):e62823.
［25］王红艳,龙捷,涂永生. 辛伐他汀抑制人非小细胞肺癌H460细胞迁移和MMP2的表达［J］. 中国临床药理学与治疗学,2015,20(7):732-735.
［26］Zhong S, Zhang X, Chen L, et al. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies［J］. Cancer Treat Rev,2015,41(6):554-567.
［27］Bansal D, Undela K, D'Cruz S, et al. Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies［J］. PLoS One,2012,7 (10): e46691.
［28］Raval AD, Thakker D, Negi H, et al. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis［J］. Prostate Cancer Prostatic Dis,2016,19(2):151-162.
［29］Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer［J］. J Clin Oncol,2014,32(1):5-11.
［30］Allott EH, Howard LE, Cooperberg MR, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database［J］. BJU Int,2014,114(5):661-666.
［31］Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis［J］. Sci Rep, 2016,6:29106.
［32］van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition［J］. Gut, 2011,60(8):1094-1102.
［33］Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer［J］. N Engl J Med, 2005,352(21):2184-2192.
［34］Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population［J］. J Natl Cancer Inst,2008,100(2):134-139.
［35］Cai H, Zhang G, Wang Z,et al. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis［J］. PLoS One,2015,10(6):e0126944.
［36］Mamtani R, Lewis JD, Scott FI, et al. Disentangling the association between statins, cholesterol, and colorectal cancer: a nested case-control study［J］. PLoS Med,2016,13(4):e1002007.
［37］Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803［J］. J Natl Cancer Inst, 2011,103(20):1540-1551.
［38］Mace AG, Gantt GA, Skacel M, et al. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer［J］. Dis Colon Rectum,2013,56(11):1217-1227.
［39］Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies［J］. Breast Cancer Res Treat,2012,135(1):261-269.
［40］McDougall JA, Malone KE, Daling JR, et al. Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age［J］. Cancer Epidemiol Biomarkers Prev,2013,22:1529-1537.
［41］Mansourian M1, Haghjooy-Javanmard S, Eshraghi A, et al. Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies［J］. J Pharm Pharm Sci,2016,19(1):72-81.
［42］Nickels S, Vrieling A, Seibold P, et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort［J］. PLoS One,2013, 8 (9): e75088.
［43］Wu Q J, Tu C, Li YY, et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis［J］. Oncotarget,2015,6:42988-43004.
［44］Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis［J］. Ann Oncol,2013,24(7):1721-1730.
［45］Tan M, Song X, Zhang G, et al. Statins and the risk of lung cancer: a meta-analysis［J］. PLoS One,2013,8(2):e57349.
［46］Lin JJ, Ezer N, Sigel K,et al. The effect of statins on survival in patients with stage IV lung cancer［J］. Lung Cancer,2016,99:137-142.

[1]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[2]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[3]	ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei. Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
[4]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[5]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[6]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[7]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[8]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[9]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[10]	WANG Xin, SUN Heliang, ZHANG Qingwei, LIU Cunming, WANG Zhongyun, YANG Chun. Postoperative analgesic effect of low-dose esketamine in patients with thoracoscopic lobectomy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 998-1003.
[11]	HUA Haiyan, YAN Jie, QIN Yufen. Experimental study of schisandrin B attenuates acute myocardial ischemia injury in rats by inhibiting cardiomyocyte apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 848-856.
[12]	LI Xueheng, LI Long. Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
[13]	YANG Liu, LUO Ailin, LI Shiyong. Advance of general anesthetics-induced developing brain injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1381-1390.
[14]	TAN Fenglang, REN Hongli, WANG Hongfei. Effect of Phellodendri amurense extract on hippocampal nerve cells induced by Aβ_1-42 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1213-1220.
[15]	PAN Rongrong, ZHI Yinghao, JIN Yongxi, ZHOU Xiahui. Influences of theaflavins on neuronal apoptosis and blood-brain barrier in rats with cerebral hemorrhage by regulating CaMKK2/AMPK signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1240-1246.